When evaluating all colorectal cancer stages collectively, patients with both CD133-positive CTCs and high CEA levels demonstrated significantly poorer 5-year disease-specific survival (DSS) compared to those without this combination (60.4% vs. 80.7%, p = 0.014; Figure 5). The gene discussed is CEACAM5; the disease is colorectal cancer.